Securing the bioeconomy is an ongoing challenge for companies across the life science and pharmaceutical sectors. Though companies from both sectors continue to innovate and adopt tools like AI to drive progress, the fact of the matter remains that pharma companies lag behind other businesses when it comes to the management of digital assets. This is also true of the industry’s adoption of pertinent cybersecurity systems.
Last year, we spoke to Vishal Salvi, CISO at Infosys, and Charles Fracchia, founder BioBright and Vice-president of Data at Dotmatics, about the issue. But how have things changed since then? The industry certainly hasn’t remained stagnant and as it grows and evolves, new vulnerabilities are sure to emerge.
He joined us for our inaugural Big Question – an anthology of articles exploring whether pharma can be remodeled using AI – to share his thoughts on pharma’s relationship with cybersecurity and how the increased use of AI will impact it.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
